The FirstWord Pharma Daily News Round-Up Video gives a recap of the latest pharmaceutical and biotechnology news. Stay abreast of the key industry news each day. Today’s video highlights include Novartis, Selexys Pharmaceuticals, SelG1, GlaxoSmithKline, fluticasone, umeclidinium, vilanterol, Acorda Therapeutics, Ampyra, CVT-301, tozadenant, CVT-427, SYN120 and rHIgM22.
Welcome to first white farmers news roundup for november 21st brought to you today by the torial researcher nina whittle in our top news story novartis has acquired celexa pharmaceuticals following results of the phase to sustain study evaluating the experimental anti p-selectin antibody sell g1 for the reduction of azo occlusive pain crises and patients with
Sickle cell disease according to novartis terms of the deal crow total up to 665 million dollars in upfront acquisition and milestone payments also in the news flexo smithkline has submitted a marketing application to the fda for its closed triple combination therapy for use in patients with chronic obstructive pulmonary disease the combination therapy comprises
The inhaled corticosteroid fluticasone furoate the long-acting muscarinic antagonist jamel adenium and the long-acting beta 2 adrenergic agonist vilanterol delivered once daily vial glaxosmithkline’s ellipta dry powder inhaler dave allen head of respiratory r&d at glaxosmithkline noted this first regulatory submission of our clothes triple therapy brings
Us a step closer to providing a once-daily treatment in a single ellipta inhaler as an alternative option for those patients who require multiple therapies in june the company’s indicated that the therapy would likely be submitted for us approval by the end of the year ahead of a previously planned filing anticipated in the first half of 2018 and finally acorda
Therapeutics disclosed that results from the mid stage milestone trial did not show sufficient efficacy to support further development of ampara to improve post-stroke walking difficulties results from the trial showed that fourteen percent of patients in the low dose ampara group and nineteen percent of those in the high dose group achieved at least twenty percent
Improvement in the two minute walk test compared with 13.5 percent for placebo ceo ron coan remarked the study indicated there was activity related to walking in people with post-rock walking difficulties as suggested by the prior phase 2 study but overall this was not sufficiently clinically meaningful cohen said we plan to focus r&d resources on developing
Our promising late stage parkinson’s disease therapies cvt 301 and toes a tenant as well as advancing our earlier stage assets cvt 427 in migraine sy n 120 in parkinson’s disease dementia and a reminder nating antibody in multiple sclerosis to read these and other stories info please visit first blood farmer calm are you able to keep up with all the news and views
In the biosimilars market first words biosimilar index is the only dedicated biosimilar and non comparable biologics intelligence tool available get ahead of your competition and learn more today
Transcribed from video
FirstWord Pharma Daily News Round-Up Video for November 21, 2016 By FirstWordPharma
